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INTRODUCTION
Due to the development of new anti-cancer drugs and new
treatment techniques, as well as many advances in the field
of stem cell transplantation and better supportive care, many
malignancies can now be treated more effectively. However,
neutropenia and infectious complications that inevitably
develop following chemotherapy, continue to be a frequent
cause of morbidity and mortality. Neutropenic fever is a
potentially life-threatening complication that requires prompt
medical intervention. Therefore, empirical antimicrobial ther-
apy without waiting for microbiological and/or clinical doc-
umentation of an infection is justified in patients with neu-
tropenic fever. Because of this, a practical treatment guide-
line suitable for the conditions unique to Korea is required.
However, it is important to ensure that this guideline takes
into account the microbiologic epidemiology, antimicrobial
resistance patterns and currently available antimicrobial drugs,
while also considering economic issues.
In Korea, there are currently 36 hematopoietic stem cell
transplantation (HSCT) centers, in which curative treatments
for hematologic diseases have been performed over 20 yr.
Nevertheless, a Korean guideline for the treatment of neu-
tropenic fever has not been established yet. And the guide-
line produced by the Infectious Diseases Society of America
(IDSA) has primarily been used. However, this guideline
was established on conditions unique to the Unites States.
Therefore, its application in Korea, causes many problems.
For example, differences are caused by general factors, such
as characteristic racial factors and the socio-cultural environ-
mental factors. In addition, the local medical system and
insurance coverage criteria are different. In more detail, the
types of licensed antimicrobials and approved ranges and
dosages are different. For these reasons, countries other than
the U.S.A., such as Germany, France, Italy, and Japan, have
begun to prepare guidelines specific to their own country
(2-5). Therefore, we have performed this nationwide survey
to define the current clinical practices in place for the man-
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Current Antimicrobial Usage for the Management of Neutropenic
Fever in Korea: A Nationwide Survey
A nationwide questionnaire-based survey was performed to evaluate the current
clinical practices for the management of neutropenic fever in hematology units and
hematopoietic stem cell transplantation (HSCT) centers throughout Korea. A 86.9%
response rate was obtained from a total of 46 doctors and practical policies of the
33 sites were analysed. Approximately 42.4% and 84.8% of the sites responded
that they used oral fluoroquinolone as prophylaxis for neutropenic patients receiv-
ing chemotherapy and HSCT, respectively. Additionally, 42.4% of the sites respond-
ed that they used antifungal prophylaxis in the chemotherapy groups whereas 90.9%
of the sites responded that they used antifungal prophylaxis in HSCT recipients.
Approximately half of the responding sites prescribed combination regimen with
3rd or 4th cephalosporin plus aminoglycoside as a first-line therapy. Most of the
sites considered persistent fever for 2-4 days or aggravated clinical symptoms for
1-2 days as failure of the first-line regimen, and they changed antibiotics to sec-
ond-line regimens that varied widely among the sites. Twenty-seven sites (84.4%)
responded that they considered adding an antifungal agent when fever persisted
for 5-7 days despite antibacterial therapy. Amphotericin B deoxycholate was pre-
ferred as a first-line antifungal, which was probably due to the limitations of the
national health insurance system. The role of oral antibiotics in the management of
neutropenic fever still accounted for a small portion. To the best of our knowledge,
this survey is the first report to examine the practical policies currently in place for
the management of neutropenic fever in Korea and the results of this survey may
help to establish a Korean guideline in the future.
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Accepted : 4 March 2008agement of neutropenic fever in each HSCT center and hema-
tologic unit in Korea as a first step towards the development
of guideline that is suitable for the actual circumstances of
our country.
MATERIALS AND METHODS
A questionnaire was sent out to selected hematologists
and infectious disease specialists in each HSCT center and
hematology unit in Korea. The survey was designed to assess
the practical policies currently in place with respect to the
definition of neutropenic fever, prophylactically and empiri-
cally used antimicrobials. In addition, the definition of treat-
ment failure and the indications for colony stimulating fac-
tor (CSF) treatment and granulocyte transfusion used for the
management of neutropenic fever at each site were also asked.
When different guidelines were applied between the che-
motherapy group and HSCT group, it was recorded sepa-
rately to distinguish them. The letter accompanying the
questionnaire stressed that the answers should be based on
local unit policies and not on personal opinions. This survey
was conducted between December 2005 and February 2006.
If there were different answers between the hematologist
and infectious disease specialist from a center, we verified
the data through direct contact by e-mail or telephone to
the responsible person in charge. And practical policies were
investigated for each of adult and pediatric patients at HSCT
centers or hematologic units (from here on, the word ‘site’
refers to the HSCT center and hematology unit). The results
were entered into SPSS 13.0 (SPSS Korea, Seoul, Korea) and
analyzed using the accompanying software.
RESULTS
General aspects
Questionnaire was sent to 46 doctors (34 that belonged
to the department of internal medicine and 12 that belonged
to the department of pediatrics) at 34 university hospitals,
and 40 (86.9%) of the doctors (34 from the department of
internal medicine and 6 from the department of pediatrics)
responded. Thirty-four replies from the department of inter-
nal medicine included duplicated answers from hematolo-
gists and infectious disease specialists at 7 HSCT centers.
After verification of the data, practical policies of the 33 sites
were obtained from 28 university hospitals throughout Korea
(Fig. 1).
Twenty-seven (81.8%) of the 33 sites that responded had
their own policies regarding the treatment of neutropenic
fever, however most of the sites (21/33, 77.8%) based their
policies on the IDSA guideline, and only 5 sites (18.5%)
used guidelines that they had prepared based on their own
microbiologic data. Thirteen of the sites (39.4%) approached
the treatment of neutropenic fever by dividing patients into
the high risk group and the low risk group; however, only 3
of these sites actually administered oral antibiotics to the
low risk group.
Currently used definition
The currently used definition of neutropenic fever varied
among the sites. Neutropenia was defined as the presence of
a neutrophil count of <500 cells/μ L or a neutrophil count of
<1,000 cells/μ L that was predicted to decrease to <500 cells/
μ L by 31 sites (93.9%). However, fever was defined as a sin-
gle temperature of ≥38.0℃ or a temperature of ≥38.0℃
for >1 hr by 20 sites (60.6%), whereas 2 separate tempera-
ture of ≥38.0℃ or a temperature of ≥38.0℃ for >1 or 2
hr was used to define fever in 6 sites (18.2%), and a single
temperature of ≥38.3℃ was used in 4 sites (12.1%). Three
sites (9.1%) considered ≥37.8℃ as fever. Another point to
be considered was that only 2 sites (6.0%) measured the oral
temperature as specified in the IDSA guideline, whereas most
sites measured the axillary or tympanic membrane tempera-
ture (31/33, 93.9%). Also, definition of the fever was not
differently applied according to the measured sites.
Prophylaxis
Antimicrobial prophylaxis was administered to chemother-
apy patients in 19 sites (57.6%). Both antibacterial and anti-
fungal prophylaxis was done in 12 sites (36.4%). Two sites
(6.1%) prescribed only an antibacterial agent and another 2
sites administered only antifungal agents to chemotherapy
groups. Furthermore, 3 sites (9.1%) provided only anti-pneu-
mocystis prophylaxis and 1 sites provided anti-tuberculous
prophylaxis with isoniazid (300 mg/day) to patients who
had a past history of tuberculosis and a suspicious lesion on
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Questionnaire
Sent to 46 doctors (34 university hospitals)
∙ ∙34: Dept. of internal medicine
∙ ∙12: Dept. of pediatrics
Answered from 40 doctors
∙ ∙34: Dept. of internal medicine
∙ ∙6: Dept. of pediatrics
6: No reply 
Data from 33 sites (28 university hospitals)
∙ ∙27: Dept. of internal medicine
(16 hematologists & 11 infectious disease specialists)
∙ ∙6: Dept. of pediatrics
7: Duplicated replies
Fig. 1. Process of data collection.radiography. Oral ciprofloxacin and levofloxacin were used
as antibacterial agents in 11 and 3 sites, respectively.
When the HSCT group was considered, it was found that
antimicrobial prophylaxis was done in 30 sites (90.9%).
Antibacterial agents were prescribed in 28 sites (84.8%).
Oral ciprofloxacin was used as the antibacterial agent in 20
of the sites (60.6%), whereas oral levofloxacin was used in 5
of the sites (15.2%). In addition, roxithromycin or a combi-
nation of either ciprofloxacin plus metronidazole or vanco-
mycin plus colimycin (colistimethate sodium) was used oral-
ly in 1 site each. Antifungal prophylaxis was done in 30 sites
(90.9%), with oral fluconazole or itraconazole being admin-
istered in 25 of 28 sites that responded to the question, and
amphotericin B deoxycholate or nystatin also being admin-
istered in 3 sites (data were not mutually exclusive). Twen-
ty-one sites (63.6%) used oral acyclovir for antiviral prophy-
laxis, whereas intravenous (IV) acyclovir was used in 5 sites
(15.2%), and ganciclovir was used in 2 sites. Co-trimoxa-
zole was prescribed for pneumocystis prophylaxis in 29 sites
(87.9%) and it was coupled with pentamidine inhalation in
one site. Anti-tuberculous prophylaxis with isoniazid was
done in 3 sites; however different doses were used among
the sites (dose, 300-400 mg/day, or 10 mg/kg/day).
Empirical therapy and modification of initial therapy
The most commonly prescribed regimen for empirical
antibiotic therapy of neutropenic fever was one cephalosporin
(ceftazidime or cefepime) plus one aminoglycoside in 50.0%
and 43.7% of the chemotherapy and HSCT group, respec-
tively (Table 1). Overall, combination regimen using an
aminoglycoside plus either cephalosporin, carbapenem or an
antipseudomonal penicillin was used as empirical therapy
in 71.9% and 65.6% of the chemotherapy and HSCT group,
respectively. Additionally, carbapenem monotherapy was
used as an initial empirical therapy in one site for the HSCT
group.
As for glycopeptides, vancomycin was used at 17 sites
(51.5%), whereas teicoplanin was used at 10 sites (30.3%),
and both were used at 6 sites (18.2%). A glycopeptide was
routinely prescribed as part of an initial empirical therapy
in only 2 out of 22 sites that responded to the question, which
suggested that most sites do not feel that glycopeptide was
a necessary part of the initial regimen. In 19 (86.4%) of the
22 sites that responded to the question, glycopeptide was
started for selected patients based on the IDSA guideline.
And 21 out of 32 sites (65.6%) that answered the question
stated that they stopped glycopeptide when an absolute neu-
trophil count (ANC) was recovered over 500 cells/μ L and
any sign of infection by gram positive organisms disappeared.
Additionally, in 7 out of 32 sites (21.9%), glycopeptide was
discontinued immediately when signs and symptoms of infec-
tion induced by gram positive organisms disappeared regard-
less of ANC.
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Regimen
Total number of sites responded=32
Chemotherapy group N (%) HSCT group N (%)
Combination therapy 23 (71.9) 21 (65.6)
Cephalosporin+AG 16 (50.0) Cephalosporin+AG 14 (43.7)
[cefepime/3rd cephalosporin/both] [4/11/1] [cefepime/3rd cephalosporin/both] [3/11]
Piperacillin or Pip/Taz+AG 5 (15.6) Cefepime+carumonam 1 (3.1)
Ceftazidime+levofloxacin 1 (3.1) Piperacillin or Pip/Taz+AG 5 (15.6)
Ceftazidime+AG+vancomycin 1 (3.1) Ceftazidime+AG+vancomycin 1 (3.1)
Monotherapy 7 (21.9) 9 (28.1)
Cephalosporin only 6 (18.7) Cephalosporin only 6 (18.7)
[Cefepime/ceftazidime] [5/1] [Cefepime/ceftazidime] [5/1]
Pip/Taz only 1 (3.1) Pip/Taz only 1 (3.1)
Carbapenem only 1 (3.1)
Other 1 (3.1)
Both 2 (6.2) 2 (6.2)
Cefepime or ceftazidime or Pip/Taz±AG 2 (6.2) Cefepime or ceftazidime or Pip/Taz±AG 2 (6.2)
Table 1. Empirical antimicrobial regimens in the treatment of neutropenic fever
HSCT, hematopoietic stem cell transplantation; AG, aminoglycoside; Pip/Taz, piperacillin/tazobactam.
Total number of sites that responded=33 N (%)
Persistent fever for 2-3 days 5 (15.1)
Persistent fever for 2-3 days or aggravated  20 (60.6)
clinical symptom in 1-2 days
Persistent fever for 3-4 days 4 (12.1)
Persistent fever for 3-5 days or aggravated  2 (6.1)
clinical symptom in 1-2 days
Persistent fever for 3-7 days or aggravated  1 (3.0)
clinical symptom in 1-2 days
Second set fever or septic shock 1 (3.0)
Table 2. Criteria for changing the initial empirical regimenTable 2 shows the criteria used for changing the initial
empirical regimen. Most of sites considered persistent fever
for 2-4 days or aggravated clinical symptoms for 1-2 days as
failure of the first-line antibiotics. Table 3 shows the antibac-
terial agents that were prescribed as second-line regimens.
The most common approach was to add a glycopeptide regard-
less of signs of gram positive infection and change to the
second-line regimens. The second-line regimens were as fol-
lows: carbapenem with or without aminoglycoside was con-
sidered for cases in which cephalosporin or piperacillin/
tazobactam was used as the first-line regimen, and cefepime,
ceftazidime, or piperacillin/tazobactam with or without
aminoglycoside was used for cases in which piperacillin was
used as the first-line regimen.
Empirical antifungal and antiviral therapy
Table 4 presents the conditions under which antifungal
therapy was started. Twenty-seven sites (84.4%) considered
adding an antifungal agent after 5-7 days of persistent fever
despite antibacterial therapy. And 14 sites initially prescribed
antifungal agents to the patients who had a history of inva-
sive fungal infection during a previous chemotherapy. Table
5 shows the first-line antifungal agents used for treatment
of persistent neutropenic fever. In cases receiving antifungal
prophylaxis, amphotericin B deoxycholate or IV itracona-
zole were used as the antifungal agents of choice in 25 of 26
sites that responded. Whereas, in cases without antifungal
prophylaxis, they were the agents of choice in 17 of 18 sites
that responded. Out of 18 sites that responded the rank of
preference, 12 sites used amphotericin B as the first-line anti-
fungals and 6 sites used IV itraconazole as the first-line anti-
fungals. Twenty-two sites responded that they switched to
the second-line antifungal agents if persistent fever or deter-
ioration of radiological findings occurred after administra-
tion of the first-line antifungal agents for 7-10 days. They
responded a great variety of second-line antifungal angents
such as caspofungin, voriconazole, itraconazole IV, Ampho-
tericin B deoxycholate, liposomal amphotericin B, and flu-
conazole (only in cases of candidemia).
Empirical antiviral therapy was conducted at 20 sites (60.6
%), 17 of which responded that they administered acyclovir
in cases of vesicular skin eruption suspicious herpesvirus
infection or intractable oral ulcer. Three sites responded that
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*, Galactomannan assay was used at 3 centers.
Total number of sites responded=32 N (%)
Initial use of antifungals with first line antibacterial agents 15 (46.8)
Past history of invasive fungal infection±high dose  14
of steroid
Past history of invasive fungal infection±suspicious lesion 1
Not initially but clinical symptom and sign such as
Pulmonary infiltrate during broad spectrum  28 (87.5)
antibacterial therapy
Halo sign on chest CT scan 29 (90.6)
Facial swelling and tenderness 17 (53.1)
Necrotic escar on perinasal area 19 (59.4)
Positive result of culture or non-culture method*  22 (68.7)
for fungus
Fever during recovery phase of neutropenia 10 (31.2)
Isolation of fungus from sputum 12 (37.5)
Persistent fever despite antibacterial treatment 
without any of the above sign for
1-2 days 1 (3.1)
3-5 days 3 (9.4)
5-7 days 27 (84.4)
7-14 days 1 (3.1)
Table 4. Time and situation to start antifungal agents
cAMB, conventional amphotericin B; LAMB, liposomal amphotericin B.
Antifungal agents
In patients with 
prophylaxis 
N (%)
In patients with-
out prophylaxis
N (%)
cAMB 12 (46.1) 12 (66.7)
Itraconazole (IV) 6 (24.8) 4 (22.2)
cAMB or itraconazole (IV) 7 (26.9) 1 (5.5)
Fluconazole (IV) 0 (0) 1 (5.5)
LAMB 1 (3.8) 0 (0)
Total 26 (100) 18 (100)
Table 5. First-line antifungal agents in persistent neutropenic fever
*, Data were not mutually exclusive.
ANC, absolute neutrophil count.
Total number of sites responded=33 N* (%)
Recovery of neutropenia±no infection sign/symptom 31 (93.9)
Regardless of ANC+no infection sign/symptom 6 (18.1)
Afebrile for 2 days 6
Afebrile for 3-5 days 18
Afebrile for 7 days 6
Afebrile for 14 days 2
No specific duration 5
Table 6. Duration of antimicrobial therapy
AG, aminoglycoside; GPC, gram-positive cocci.
Antibiotic regimen (total number of sites responded=33) N (%)
Add of or change to cephalosporin, AG or 5 (15.2)
carbapenem (no glycopeptide)
Continue with 1st-line antibiotics+glycopeptide 4 (12.1)
Change to 2nd-line antibiotics + glycopeptide 9 (27.3)
Change to 2nd-line antibiotics or add glycopeptide 4 (12.1)
Change to 2nd-line antibiotics+glycopeptide in case 11 (33.3)
of GPC infection
Second-line antibiotics other than glycopeptide 
(total number of sites responded=32)
Carbapenem±AG 26 (81.3)
Carbapenem or cefepime/ceftazidime/tazocin±AG 6 (18.7)
Table 3. Second-line antibiotics prescribed to patients who did
not respond to the initial empirical regimenthey prescribed acyclovir in cases of unspecified interstitial
pneumonia or encephalitis accompanying a change in men-
tal status.
Colony stimulating factor and granulocyte transfusion
CSF therapy was routinely administered at 21 sites (63.6%)
under the following conditions; 1) when the ANC was <500/
μ L in 15 sites (71.7%), 2) at a defined time after chemother-
apy or HSCT regardless of ANC in 2 sites (9.5%), 3) depend-
ing on regimen in 2 sites (9.5%), and 4) other reasons in 2
sites (9.5%).
Granulocyte transfusion was used in 14 sites (42.4%) under
the following conditions: 1) when refractory infection occurred
despite optimal antimicrobial therapy and neutropenia per-
sisted (10 sites, 71.4%), 2) 1) plus reversibility of neutrope-
nia (2 sites, 14.3%), and 3) 1) plus localized infection (2 sites,
14.3%)
Duration of antimicrobial therapy
Most sites terminated antimicrobial therapy when recov-
ery of neutropenia was coupled with the disappearance of
fever (Table 6). Additionally, six sites (18.1%) reported that
antibiotics were terminated regardless of ANC when signs
and symptoms of infection disappeared. However, the afebrile
period required to stop antibiotics varied from 2 days to 14
days.
DISCUSSION
In Korea, HSCT has been performed in more than 5,000
patients since it was first conducted in 1983. In 2006, approx-
imately 1,300 patients received HSCT and this number is
expected to continue to rise (personal communication with
Korean Stem Cell Transplantation Nurses Association). How-
ever, there is no nationwide database system currently avail-
able for the collection and analysis of data. Therefore, it is
difficult to establish a national consensus for the antimicro-
bial treatment of neutropenic fever following HSCT and
chemotherapy. In the late 90s, a survey entitled, ‘the appro-
priateness of the therapeutic use of antibiotics in patients
with neutropenic fever’ was conducted in Korea (6). That
survey, however, only evaluated the antibiotics used empiri-
cally for neutropenic fever at 15 hospitals and then simply
compared the result with guidelines of other countries. In
addition, the survey did not assess the practical policies com-
prising the overall management of neutropenic fever. In
2003, efforts were made to establish a Korean guideline for
the treatment of neutropenic fever by the Korean Society of
Chemotherapy. However, an evidence-based guideline could
not be established due to insufficient data studied within
our country. Therefore, they had suggested a recommenda-
tion based on already existing guidelines such as IDSA at
that time. So, this study is the first nationwide attempt to
survey the overall practical policies regarding the manage-
ment of neutropenic fever at hematology units or HSCT
centers in Korea.
The results of this survey showed that oral fluoroquinolones
are now widely used as prophylaxis in neutropenic patients.
We found that 57.6% and 90.9% of patients who under-
went chemotherapy and HSCT received antimicrobial pro-
phylaxis, respectively. A recent meta-analysis found that
fluoroquinolone prophylaxis reduced all-cause mortality in
neutropenic patients with hematologic malignancy when
compared to patients that did not receive antibiotic prophy-
laxis (7). However, ciprofloxacin is known to be an indepen-
dent risk factor for the acquisition of methicillin resistant
Staphylococcus aureus (8), and it is also believed that it is con-
tributing to an increase in fluoroquinolone resistance among
Escherichia coli that has already been observed in Korea (9,
10). So, it is necessary to define criteria such as to whom give
the oral prophylaxic antibiotics-e.g., patients who were sus-
pected to have prolonged neutropenia for more than 7 days.
Although recent meta-analyses have indicated that the
use of antibiotic monotherapy (11, 12) or oral antibiotics is
effective for patients with neutropenic fever at low risk (13,
14), the most commonly used empirical regimen for neu-
tropenic fever is 3rd or 4th generation cephalosporin (cef-
tazidime or cefepime) in combination with aminoglycosides.
Monotherapy was conducted in only 20% of the sites and
oral antibiotics were used in only 9.1% of the sites that res-
ponded to this survey. This is probably because prophylactic
oral antibiotics had already been administered to most patients,
which might lead to the belief that oral antibiotics could
not be administered to patients that developed fever. How-
ever, the low cost of hospitalization in Korea compared with
that of other countries, coupled with the emotional trait of
patients and doctors’ desire to avoid ambulatory treatments
at outpatient clinics may also play a role in the choice of IV
antibiotics. Therefore, carefully designed studies are needed
to specify the conditions under which outpatient therapy is
an acceptable and perhaps preferred choice for neutropenic
fever in our country. The results of this survey also showed
that only 2 sites (6.2%) routinely used a glycopeptide at the
beginning of empirical therapy. These results are similar to
those of a multicenter study (15) that failed to demonstrate
that the addition of empirical vancomycin was beneficial, as
well as to the results of a recent meta-analysis, which con-
cluded that it is safe to defer the use of glycopeptides until a
resistant gram-positive organism is documented (16). As we
knew that the criteria to define fever and measuring methods
were diverse among the sites and even within a site, a future
guideline should include practically applicable criteria which
clearly state these points. In addition, it should be kept in
mind that empirical antibiotics should be initiated regard-
less of fever if signs or symptoms of infection are present (1).
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or fever persists after 2-4 days of first-line empirical antibac-
terial therapy, most sites considered switching antibiotics to
the second-line regimens, which were very diverse as shown
in Table 3.
Most of the sites (84.4%) responded that empirical anti-
fungal therapy was considered if fever persisted more than
5-7 days of broad spectrum antibacterial therapy. Liposomal
amphotericin B was recommended by several evidence-based
guidelines (1-3, 17) and caspofungin was approved for the
persistent neutropenic fever by the Food and Drug Admin-
istration (FDA) (18). Itraconazole was also approved as a first-
line empirical antifungals for the persistent neutropenic fever
by Korean FDA. On the other hand, amphotericin B deoxy-
cholate causes many adverse events including infusion relat-
ed toxicities, nephrotoxicity, other chronic reactions such as
nausea, anorexia, vomitin, etc. Nevertheless, amphotericin
B deoxycholate has been the drug of choice because its broad
spectrum, low cost and coverage by medical insurance were
firstly considered when doctors determined a course of anti-
fungal treatment. However, pharmaco-economic studies
including cost-effectiveness during the entire treatment peri-
od should be conducted. And the selection based not only
on the daily cost of drugs, but on the cost-effectiveness data
supported by pharmaco-economic study, should be made.
Additionally, because of the wide variety of antifungal agents
used for the second-line regimen, a more comprehensive
and structural survey dealing with antifungal agents should
be conducted in the future.
Regarding the administration of CSF and granulocyte trans-
fusion, it appeared to be performed under similar criteria as
other countries (19-21). Although the effectiveness of gran-
ulocyte transfusion was limited, a favorable response was
observed in approximately 60% of cases in whom it is used
(22). Because cases requiring granulocyte transfusion are
increasing gradually, further studies should be conducted to
determine under what conditions it should be used.
It was difficult to arrange the data because there were many
differences in the policies between hematologists and infec-
tious disease specialists who even belonged to the same sites.
These differences might have occurred because the infectious
disease specialists were actively involved in the management
of febrile neutropenic patients in some centers, but not in the
others. Additionally, the differences in their opinions might
have occurred because the doctors looked at the patients from
their own special point of view. Because neutropenic fever is
an important problem to both hematologists and infectious
disease specialists, members of these two fields should always
communicate closely with each other when they treated pati-
ents as well as they decided upon new treatment strategy.
In conclusion, oral fluoroquinolones were widely used for
the prophylaxis of neutropenic fever and combination of a
cephalosporin such as ceftazidime or cefepime plus an amino-
glycoside was commonly used as a first-line therapy for neu-
tropenic fever in Korea. Although this first-line regimen
was common, very diverse protocols were used among the
sites. However, it should be noted that this survey did not
take into account selection of treatment regimens based on
microbiologic data generated at each site, and therefore, addi-
tional surveys should be accompanied. As a result of these
series of process, an evidence-based guideline specific to our
country could be prepared and standardization at a certain
level might be possible among the sites. We hope that the
results of this survey may help to establish a Korean guide-
line in the future.
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